NCT06656702View on ClinicalTrials.gov

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

July 1, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Psilocybin

Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.

Trial Locations (1)

21224

RECRUITING

Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Johns Hopkins University

OTHER